Anti-Cancer Agents in Medicinal Chemistry
Title:Meet Our Editorial Board Member
Volume: 16 Issue: 12
Author(s):
Affiliation:
Export Options
About this article
Cite this article as:
, Meet Our Editorial Board Member, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (12) . https://dx.doi.org/10.2174/187152061612161104160937
DOI https://dx.doi.org/10.2174/187152061612161104160937 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
36
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Liposomes and Lipid Envelope-Type Systems for Systemic siRNA Delivery
Current Pharmaceutical Design Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Vitamin D and miRNAs in Cancer
Current Gene Therapy Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Future Contrast Agents for Molecular Imaging in Stroke
Current Medicinal Chemistry The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations
Current Vascular Pharmacology The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in Early Diabetic Retinopathy
Current Molecular Medicine Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Synthesis and Biological Evaluation of 3,4-Dihydro-3-(3-methylisoxazol-5- yl)-2H-benzo[e][1,3]oxazine Derivatives as Anticancer Agents
Letters in Organic Chemistry Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives
Current Drug Therapy Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Molecular Modelling Studies on Thiazole-Based α-Glucosidase Inhibitors Using Docking and CoMFA, CoMSIA and HQSAR
Current Drug Discovery Technologies The Therapeutic Potential of Gallium-Based Complexes in Anti-Tumor Drug Design
Letters in Drug Design & Discovery Sphingosine Analogs and Protein Phosphatase 2A as a Molecular Targeted Cancer Therapy: A Mini Systematic Review
Clinical Cancer Drugs Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics